SynthesisBMC infectious diseases2021
Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Trial
- Clinical characteristics and prognostic factors influencing respiratory syncytial virus pneumonia in children with atopy: a retrospective cohort study.Translational pediatrics · 2026Article
- Clinical characteristics and risk factors associated with mortality in hospitalized patients with COVID-19 aged 90 years or older.Medicine · 2026Article
- Long-term radiologic trajectories and corticosteroid strategies in COVID-19 patients with pre-existing ILD: a 24-month cohort study.BMC pulmonary medicine · 2026Article
- Glucocorticoids suppress early lung inflammation and impair control of SARS-CoV-2 in non-human primates.PloS one · 2026Article
- Article
- Article
- Interplay between endogenous hormones and immune systems in human metapneumovirus pathogenesis and management.Frontiers in pharmacology · 2025Review
- Article
- Relapse of COVID-19 and Viral Evolution in a Patient With Good Syndrome: A Case Report.Cureus · 2024Article
- Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study.Frontiers in cellular and infection microbiology · 2024Article
- Effect of Immunosuppressive or Immunomodulatory Agents on Severe COVID-19 Outcomes: A Population-Based Cohort Study.ACR open rheumatology · 2023Article
- In-hospital adverse outcomes and risk factors among chronic kidney disease patients infected with the omicron variant of SARS-CoV-2: a single-center retrospective study.BMC infectious diseases · 2023Article
- Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.Clinical and experimental medicine · 2023Article
- Factors Associated With Prolonged Ventilation in Patients Receiving Prone Positioning Protocol With Muscle Relaxants for Severe COVID-19 Pneumonia.Respiratory care · 2023Article
- Pituitary Diseases and COVID-19 Outcomes in South Korea: A Nationwide Cohort Study.Journal of clinical medicine · 2023Article
- Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy.Endocrinology and metabolism (Seoul, Korea) · 2023Article
- GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection.The European respiratory journal · 2023Article
- IL-2 and IL-1β Patient Immune Responses Are Critical Factors in SARS-CoV-2 Infection Outcomes.Journal of personalized medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEvidence of glucocorticoids on viral clearance delay of COVID-19 patients is not clear.
methodsIn this systematic review and meta-analysis, we searched for studies on Medline, Embase, EBSCO, ScienceDirect, Web of Science, Cochrane Library, and ClinicalTrials.gov from 2019 to April 20, 2021. We mainly pooled the risk ratios (RRs) and mean difference (MD) for viral clearance delay and did subgroup analyses by the severity of illness and doses of glucocorticoids.
results38 studies with a total of 9572 patients were identified. Glucocorticoids treatment was associated with delayed viral clearance in COVID-19 patients (adjusted RR 1.52, 95% CI 1.29 to 1.80, I
conclusionsGlucocorticoids treatment delayed viral clearance in COVID-19 patients of taking high doses or medium doses, rather in those of taking low doses of glucocorticoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.